A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder

British Journal of Psychiatry

Fecha de publicación: 17 de noviembre de 2021

Autores: Jon E. Grant, Stephanie Valle, Eve Chesivoir, Dustin Ehsan and Samuel R. Chamberlain

DOI: https://doi.org/10.1192/bjp.2021.159

Background: Borderline personality disorder is associated with impaired quality of life and has a number of untoward public health associations. There is no established first-line pharmacological treatment for borderline personality disorder, and available options are not suitable for all individuals.

Enviar comentario